The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Fewer GI, GU Toxicities With Postoperative Pelvic IMRT in Gynecologic Malignancies
September 29th 2016Patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity when treated with pelvic intensity-modulated radiation therapy as opposed to standard pelvic radiation therapy.
Expert Sheds Light on Issues With ASCO-CAP HER2 Guidelines
September 27th 2016Michael F. Press, MD, PhD, discusses a retrospective study comparing the original FDA-approved criteria for HER2 gene amplification in breast cancer with the current ASCO-CAP guidelines, and exactly how the 2 sets of guidelines differ from one another.
Frontline Carfilzomib Not Superior to Bortezomib in Phase III Myeloma Study
September 27th 2016Carfilzomib did not improve progression-free survival compared with bortezomib when used in combination with melphalan and prednisone as a treatment for transplant ineligible patients with newly diagnosed multiple myeloma.
Study Suggests Superiority of Functional Imaging in Assessing Sarcoma Outcomes
September 26th 2016A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses.
Encorafenib/Binimetinib Combo Improves PFS Versus Vemurafenib in Phase III Melanoma Study
September 26th 2016The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improved progression-free survival compared with single-agent vemurafenib for patients with BRAF-mutant melanoma.
Anti-Nausea Benefit Observed With Olanzapine in Patients Receiving HEC Regimen
September 26th 2016For patients receiving highly emetogenic chemotherapy, olanzapine (Zyprexa) was found to demonstrate a significant improvement in the prevention of nausea when it was added to a standard antiemetic regimen.
Pembrolizumab Approval Is Tip of the Iceberg for Immunotherapy in HNSCC
September 21st 2016Barbara A. Burtness, MD, discussed the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.
Expert Discusses Immense Impact of Immunotherapy in GU Cancers
September 21st 2016Elizabeth Plimack, MD, discusses some of the most impressive advancements with immunotherapy agents in the fields of renal cell carcinoma and bladder cancer, as well as remaining questions with the use of these treatments.
Raising Issues and Developing Solutions at the Ruesch Center Policy Briefing
September 21st 2016The moonshot was one of many topics discussed at a September 14 policy briefing held by the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center. Participants also discussed the growing cost of cancer research and the implications for policy makers, health care professionals, patients and society.
EMA Initiates Official Review of Nivolumab in Bladder Cancer
September 20th 2016The European Medicines Agency has validated a type II variation application for use of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma who have progressed following platinum-based chemotherapy.
Study Addresses Appropriate Clinical Use of PSA Trial Data in Prostate Cancer
September 19th 2016A treatment recommendation based on reduced prostate-specific antigen failure observed from early results of randomized controlled trials is not likely to prolong survival in men with moderate-to-severe comorbidities.
Anti-CD19 CAR T-Cell Therapy Induces Significant Remission Rates in B-Cell ALL
September 19th 2016Chimeric antigen receptor T-cell therapy targeting CD19 demonstrated a nearly 80% complete remission rate across relapsed/refractory B-cell acute lymphoblastic leukemia patients with multiple levels of disease burden.
CHMP Issues Positive Opinion for Palbociclib in HR+/HER2- Breast Cancer
September 17th 2016The Committee for Medicinal Products for Human Use has recommended approval of palbociclib for patients with HR-positive, HER2-negative metastatic breast cancer, either in combination with an aromatase inhibitor in the frontline setting, or combined with fulvestrant after progression on endocrine therapy.
CHMP Adopts Positive Opinion for Olaratumab in Soft Tissue Sarcoma
September 16th 2016The Committee for Medicinal Products for Human Use has recommended approval of the PDGFRα antagonist olaratumab for use in combination with doxorubicin for patients with advanced soft tissue. sarcoma who are not good candidates for radiotherapy or surgery.